4-methyl-2,3,4,5-tetrahydro-benz[f][1,4]oxazepine | 113511-34-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-methyl-2,3,4,5-tetrahydro-benz[f][1,4]oxazepine
• 英文别名: 4-Methyl-2,3,4,5-tetrahydro-benz[f][1,4]oxazepin；4-Methyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine；4-methyl-3,5-dihydro-2H-1,4-benzoxazepine
• CAS: 113511-34-5
• 化学式: C₁₀H₁₃NO
• 分子量: 163.219
• InChiKey: DKOQEDREYIBUQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 potassium carbonate 作用下， 生成 4-methyl-2,3,4,5-tetrahydro-benz[f][1,4]oxazepine
  参考文献：
  名称：

  Marson, Farmaco, Edizione Scientifica, 1959, vol. 14, p. 159,170

  摘要：

  DOI：

文献信息

• HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20190315766A1

  公开（公告）日：2019-10-17

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）的化合物，以及其药学上可接受的盐、酯或前药： 这些化合物抑制呼吸道合胞病毒（RSV）。本发明还涉及包含上述化合物的药物组合物，用于治疗患有RSV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的RSV感染的方法。
• Dihydrothienopyrimidines
  申请人：GERLACH Kia

  公开号：US20130196988A1

  公开（公告）日：2013-08-01

  The present invention relates to dihydrothienopyrimidines, their use as modulators of γ-secretase and to pharmaceutical compositions containing said compounds. In particular, the present invention relates to compounds which interfere with γ-secretase and/or its substrate and therefore modulate the formation of Aβ peptides.

  本发明涉及二氢噻吡嘧啶类化合物，其作为γ-分泌酶调节剂的用途，以及含有这些化合物的药物组合物。具体而言，本发明涉及干扰γ-分泌酶和/或其底物的化合物，从而调节Aβ肽的形成。
• COMPOUNDS
  申请人：HEER Jag Paul

  公开号：US20100174065A1

  公开（公告）日：2010-07-08

  The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.

  本发明涉及具有药理活性的新型噁二唑衍生物，其制备方法，含有它们的药物组合物以及它们在治疗各种疾病中的用途。
• Agents and crystals for improving excretory potency of urinary bladder
  申请人：Ishihara Yuji

  公开号：US20090264467A1

  公开（公告）日：2009-10-22

  Agents for improving potency of the urinary bladder which comprise an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action. Particularly, crystals of a tricyclic, condensed, heterocyclic derivative are provided, which possess an excellent action to inhibit acetylcholinesterase and an action to improve the excretory potency of the urinary bladder. As an example, crystals of 8-[3-[1-[(3-fluorophenyl)-methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one or a salt thereof and pharmaceutical compositions containing them are disclosed.

  提高膀胱功能的药物，包括一种非卡巴酯类胺化合物，具有乙酰胆碱酯酶抑制作用。具体而言，提供了一种三环、紧缩、杂环衍生物的晶体，其具有优异的抑制乙酰胆碱酯酶的作用和改善膀胱排泄功能的作用。例如，披露了8-[3-[1-[(3-氟苯基)-甲基]-4-哌啶基]-1-氧代丙基]-1,2,5,6-四氢-4H-吡咯并[3,2,1-ij]喹啉-4-酮或其盐以及含有它们的制药组合物。
• HIV Integrase Inhibitors
  申请人：Ueda Yasutsugu

  公开号：US20120309698A1

  公开（公告）日：2012-12-06

  The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

  本公开涉及公式I的新化合物及其盐，其抑制HIV整合酶并防止病毒整合到人类DNA中。这种作用使得这些化合物对治疗HIV感染和艾滋病有用。本发明还包括用于治疗HIV感染者的药物组合物和方法。